Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15475173 | 0.85 | HTR1D (0.33) | KCNH2MEN1KMT2ABCHEACHE | |
| SCHEMBL15475110 | 0.78 | ALOX5 (0.32) | — | |
| SCHEMBL15475108 | 0.78 | ALOX5 (0.32) | — | |
| SCHEMBL5207900 | 0.78 | AHR (0.34) | — | |
| SCHEMBL5207888 | 0.78 | AHR (0.34) | — | |
| SCHEMBL1172170 | 0.74 | TYR (0.44) | TSHRMAPK1 | |
| SCHEMBL2791518 | 0.74 | TYR (0.44) | TSHRMAPK1 | |
| SCHEMBL1172169 | 0.74 | TYR (0.44) | TSHRMAPK1 | |
| SCHEMBL15475022 | 0.71 | TUBB1 (0.51) | MEN1KMT2AMAOAMAOB | |
| SCHEMBL15475023 | 0.71 | TUBB1 (0.51) | MEN1KMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021006267-A1 | SALT OF PYRAZOLE DERIVATIVE AND PREPARATION OF PYRAZOLE DERIVATIVE | グリーン・テック株式会社 | 2021-01-14 | — | — | WO | disclosed |
| WO-2020235582-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR MOTOR NEURON DISEASE | グリーン・テック株式会社 (JP) | 2020-11-26 | — | — | WO | disclosed |
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | KCNH2 3213/4885MEN1 4146/4885KMT2A 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.